4th Quarter - Report

AMERICAN DIABETES ASSOCIATION for AMERICAN DIABETES ASSOCIATION

Firm
Client
Income
—
Expenses
$105,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R. 2028, the Continuing and Security Assistance Appropriations Act. The Association is interested in funding at the NIDDK at the NIH and funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC. H.R.5325, the Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and Preparedness Act. The Association is interested in funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC as well as funding for the NIDDK at the NIH. S. 3040, the FY2017 Labor, Health, Human Services, Education and Related Agencies Appropriations bill. The Association is interested in funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC as well as funding for the NIDDK at the NIH. H.R.5926, the FY2017 Labor, Health, Human Services, Education and Related Agencies Appropriations bill. Association is interested in funding for the Division of Diabetes Translation and the National Diabetes Prevention Program at the CDC as well as funding for the NIDDK at the NIH. S. 3000, Senate Department of Defense Appropriations Act for FY2017. Support inclusion of diabetes as a disease eligible for the Congressionally Directed Medical Research Program. Issues worked on not yet reflected in legislation: Prevention and Public Health Fund. The Association supports the Prevention and Public Health Fund established by the ACA and opposes any legislative efforts to weaken and or cut the fund. Special Diabetes Program. The Association supports reauthorization of the program and is working on permanent or multi-year renewal before the September 2017 expiration date.

LobbyistCovered position, as disclosed
EMILY ANDERSON —
LISA COX —
MEGHAN RILEY —

Contacted: Centers For Disease Control & Prevention (CDC); SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH)

Bills named: H.R. 2028 (114th), S. 3000 (114th), H.R. 5325 (114th), H.R. 5926 (114th), S. 3040 (114th)

Transportation TRA

Issues worked on not yet reflected in legislation: Commercial Driving. Interested in the status of federal regulations concerning commercial drivers licenses for individuals with insulin-treated diabetes and have met with relevant members of Congress.

LobbyistCovered position, as disclosed
EMILY ANDERSON —
MEGHAN RILEY —

Contacted: Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

H.R. 34, the 21st Century Cures Act. The Association advocated for investment in diabetes research but didnt take a formal position on the legislation. H.R. 5003, the Improving Child Nutrition and Education Act of 2016. Oppose entire bill; reauthorizes child nutrition programs. S. 3136, the Improving Child Nutrition Integrity and Access Act of 2016. Support entire bill; reforms and reauthorizes child nutrition programs. H.R. 1192/S. 586, the National Clinical Care Commission Act. Support entire bill; creates a commission to integrate federal research, prevention, and clinical efforts on diabetes and related metabolic and autoimmune diseases. Issues worked on not yet reflected in legislation: Affordable Care Act (ACA) Repeal. The Association opposes efforts in the House and Senate to repeal the ACA without simultaneously enacting a replacement bill that offers equal or greater coverage and consumer protections. This includes, but is not limited to opposing forthcoming budget reconciliation legislation. Cost of prescription drugs. The Association is concerned about the rising cost of insulin and other diabetes medications. The Association has not endorsed any legislative proposal but has advocated for Congress to hold hearings with all parties in the insulin supply chain to increase transparency and ultimately make insulin more affordable for patients.

LobbyistCovered position, as disclosed
EMILY ANDERSON —
LISA COX —
MEGHAN RILEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH)

Bills named: S. 3136 (114th), H.R. 5003 (114th), H.R. 34 (114th), S. 586 (114th), H.R. 1192 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.